Chemomab Therapeutics Ltd. American Depositary Share financials
$1.61−1.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q1 '23 Mar 31 | Q4 '22 Dec 31 | Q3 '22 Sep 30 | Q2 '22 Jun 30 | Q1 '22 Mar 31 | Q4 '21 Dec 31 | Q3 '21 Sep 30 | Q2 '21 Jun 30 | Q1 '21 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | -$9.0M | -$8.6M | -$8.3M | -$6.3M | -$5.3M | -$5.0M | -$2.9M | -$2.8M | -$1.7M |
| Net income | — | — | — | -$8.8M | -$8.3M | -$8.1M | -$6.2M | -$5.1M | -$5.0M | -$3.0M | -$2.8M | -$1.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | $-0.16 | $-0.14 | $-0.14 | $-0.11 | $-0.09 | $-0.09 | $-0.05 | $-0.05 | $-0.04 |
| EBITDA | $0.00 | $0.00 | $0.00 | -$9.0M | -$8.6M | -$8.3M | -$6.2M | -$5.3M | -$5.0M | -$2.9M | -$2.7M | -$1.7M |
| Operating cash flow | — | — | — | -$7.2M | -$5.7M | -$5.3M | -$5.7M | -$3.7M | -$2.9M | -$2.6M | -$5.6M | -$1.3M |
| Free cash flow | — | — | — | -$7.2M | -$5.7M | -$5.3M | -$5.7M | -$3.7M | -$3.0M | -$2.6M | -$5.7M | -$1.3M |
| Diluted shares | 510.2M | 359.0M | 235.0M | 55.2M | 56.3M | 57.2M | 57.0M | 57.0M | 57.2M | 57.0M | 54.1M | 39.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.6M | $6.1M | $9.3M | $20.8M | $13.5M | $10.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | — | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $13.8M | $17.0M | $22.2M | $35.0M | $43.1M | $50.2M |
| Total liabilities | $1.5M | $3.4M | $5.2M | $7.1M | $6.8M | $5.6M |
| Shareholders' equity | $12.3M | $13.5M | $17.0M | $28.0M | $36.2M | $44.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology